TOP TEN perturbations for 1552448_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552448_a_at
Selected probe(set): 1552448_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552448_a_at (1552448_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

DLBCL study 7 (plasmablast-like) / DLBCL study 7 (centroblast-like)

Relative Expression (log2-ratio):-7.0962825
Number of Samples:2 / 2
Experimental DLBCL study 7 (plasmablast-like)
Primary tumor samples from patients with unclassified diffuse large B-cell lymphoma. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to plasmablast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (centroblast-like)
Primary tumor samples from patients with unclassified diffuse large B-cell lymphoma. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to centroblast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

Burkitt lymfoma study 4 (MAP2K inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):4.2511454
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (MAP2K inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment and isolated after MAP2K inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.

brain tumor study 1 (medulloblastoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-2.4127798
Number of Samples:22 / 46
Experimental brain tumor study 1 (medulloblastoma)
Primary tumor tissue sample from the brain of patients with medulloblastoma.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

brain tumor study 1 (ependymoma) / normal brain tissue

Relative Expression (log2-ratio):2.1646118
Number of Samples:46 / 12
Experimental brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.
Control normal brain tissue
Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors.

brain tumor study 1 (glioblastoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-2.0998135
Number of Samples:34 / 46
Experimental brain tumor study 1 (glioblastoma)
Primary tumor tissue sample from the brain of patients with glioblastoma multiformae.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

brain tumor study 1 (pilocytic astrocytoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-2.0322409
Number of Samples:15 / 46
Experimental brain tumor study 1 (pilocytic astrocytoma)
Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

diabetes type 1 study 5 (longstanding) / post-mortem pancreas tissue

Relative Expression (log2-ratio):1.8434696
Number of Samples:6 / 3
Experimental diabetes type 1 study 5 (longstanding)
Pancreas tissue obtained post-mortem from patients with longstanding type 1 diabetes.
Control post-mortem pancreas tissue
Pancreatic tissue samples derived post-mortem after traumatic injury from healthy organ donors . The subjects had negative islet cell antibody test.

diabetes type 1 study 5 (longstanding) / diabetes type 1 study 5 (clinical)

Relative Expression (log2-ratio):1.5615244
Number of Samples:6 / 3
Experimental diabetes type 1 study 5 (longstanding)
Pancreas tissue obtained post-mortem from patients with longstanding type 1 diabetes.
Control diabetes type 1 study 5 (clinical)
Pancreas tissue obtained post-mortem from patients with clinical onset of type 1 diabetes.

DLBCL study 1 (activated B-cell like; plasmablast-like) / DLBCL study 1 (activated B-cell like; centroblast-like)

Relative Expression (log2-ratio):-1.3574181
Number of Samples:12 / 3
Experimental DLBCL study 1 (activated B-cell like; plasmablast-like)
Plasmablast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centroblast-like)
Centroblast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

pancreatic cancer study 2 / uninvolved pancreas tissue

Relative Expression (log2-ratio):-1.3487415
Number of Samples:39 / 38
Experimental pancreatic cancer study 2
Ductal adenocarcinoma sample obtained from patients with pancreatic cancer.
Control uninvolved pancreas tissue
Normal pancreas sample obtained from patients with pancreatic cancer.